Arizona State Retirement System Purchases 3,518 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Arizona State Retirement System grew its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 6.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,001 shares of the biotechnology company’s stock after purchasing an additional 3,518 shares during the period. Arizona State Retirement System’s holdings in BioCryst Pharmaceuticals were worth $429,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after purchasing an additional 127,708 shares during the last quarter. Fisher Asset Management LLC lifted its stake in BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after purchasing an additional 481,359 shares during the last quarter. Two Sigma Advisers LP lifted its stake in BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after purchasing an additional 261,500 shares during the last quarter. FMR LLC lifted its stake in BioCryst Pharmaceuticals by 2.4% during the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock worth $15,112,000 after purchasing an additional 46,110 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after buying an additional 91,998 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $7.70 on Friday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $9.50. The company has a market cap of $1.61 billion, a PE ratio of -12.62 and a beta of 1.85. The stock’s 50-day moving average is $8.14 and its 200 day moving average is $7.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the previous year, the company posted $0.28 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% compared to the same quarter last year. Analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BCRX shares. Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Evercore ISI lifted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, Wedbush started coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.